We recently established an immunocompetent mouse model by transplanting human nectin-4-introduced mouse cancer cells and found that intratumoral rMV-SLAMblind treatment activated natural killer (NK) cells and elicited a tumor antigen-specific CD8 T cell response in the tumor microenvironment32. This evidence concerns the gene CD8A and neoplasm.